Concord Biotech Ltd
CONCORDBIOConcord Biotech Ltd
CONCORDBIO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 68.69 | 14.75 | 0.41% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.23 | 6.64 | 0.52% |
Forecast & Ratings
Detailed Forecast from 4 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Concord Biotech Limited, a biopharma company, engages in R&D, manufacturing, and marketing of pharmaceutical products in diverse therapeutic segments.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Mankind Pharma Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 543.85 | 630.50 | 736.35 | 890.44 | 1,054.09 | 1,129.45 | ||||||
Raw Materials | 134.79 | 150.61 | 187.99 | 195.84 | 241.28 | 632.73 | ||||||
| Power & Fuel Cost | 37.30 | 39.86 | 71.64 | 97.65 | 104.97 | |||||||
| Employee Cost | 62.24 | 64.25 | 95.69 | 110.28 | 123.05 | |||||||
| Selling & Administrative Expenses | 31.74 | 31.21 | 67.90 | 82.93 | 91.08 | |||||||
| Operating & Other expenses | 41.73 | 2.98 | 19.42 | 22.51 | 24.37 | |||||||
EBITDA | 236.05 | 341.59 | 293.71 | 381.23 | 469.34 | 496.72 | ||||||
| Depreciation/Amortization | 21.25 | 27.52 | 50.05 | 54.03 | 53.59 | 53.75 | ||||||
| PBIT | 214.80 | 314.07 | 243.66 | 327.20 | 415.75 | 442.97 | ||||||
| Interest & Other Items | 1.17 | 0.90 | 6.13 | 5.18 | 3.18 | 1.30 | ||||||
| PBT | 213.63 | 313.17 | 237.53 | 322.02 | 412.57 | 441.67 | ||||||
| Taxes & Other Items | 44.53 | 77.83 | 62.59 | 81.93 | 104.46 | 113.75 | ||||||
| Net Income | 169.10 | 235.34 | 174.94 | 240.09 | 308.11 | 327.92 | ||||||
| EPS | 16.16 | 22.50 | 16.72 | 22.95 | 29.45 | 31.35 | ||||||
| DPS | 3.57 | 0.00 | 0.47 | 6.83 | 8.75 | 8.75 | ||||||
| Payout ratio | 0.22 | 0.00 | 0.03 | 0.30 | 0.30 | 0.28 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Concord Biotech Ltd | 73.11 | 14.75 | 0.41% |
| Sun Pharmaceutical Industries Ltd | 45.62 | 6.51 | 0.74% |
| Mankind Pharma Ltd | 62.83 | 12.55 | — |
| Cipla Ltd | 28.94 | 4.45 | 0.88% |
Price Comparison
Compare CONCORDBIO with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Concord Biotech Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HSBC Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8066% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months 0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 72/109 (+2) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5516% | Percentage of the fund’s portfolio invested in the stock 3.82% | Change in the portfolio weight of the stock over the last 3 months 0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/32 (-2) |
Invesco India Multicap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3311% | Percentage of the fund’s portfolio invested in the stock 1.91% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 44/73 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 21, 2024
Dividend/Share
₹8.75
Ex DateEx Date
Jun 21, 2024
Net profit of Concord Biotech rose 18.17% to Rs 95.74 crore in the quarter ended September 2024 as against Rs 81.02 crore during the previous quarter ended September 2023. Sales rose 18.23% to Rs 310.18 crore in the quarter ended September 2024 as against Rs 262.35 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales310.18262.35 18 OPM %43.1144.11 - PBDT143.65123.00 17 PBT130.34109.70 19 NP95.7481.02 18 Powered by Capital Market - Live
Concord Biotech will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
Net profit of Concord Biotech rose 9.36% to Rs 59.59 crore in the quarter ended June 2024 as against Rs 54.49 crore during the previous quarter ended June 2023. Sales rose 10.76% to Rs 215.80 crore in the quarter ended June 2024 as against Rs 194.83 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales215.80194.83 11 OPM %37.6637.03 - PBDT92.7084.08 10 PBT79.5271.04 12 NP59.5954.49 9 Powered by Capital Market - Live
Concord Biotech will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant